ASCIA Submissions 2024
ASCIA advocates on behalf of ASCIA members to government and other organisations by lodging submissions which are listed below.
- ASCIA has lodged five submissions on 24 January 2024 in support of applications for new or updated Pharmaceutical Benefits Scheme (PBS) listings of products (listed below) that are relevant to allergy and immunology. These applications are on the agenda of the March 2024 Pharmaceutical Benefits Advisory Committee (PBAC) meeting as stated on https://www.allergy.org.au/about-ascia/info-updates/pbac-meeting-march-2024.
ASCIA letter PBAC Asthma Dupilumab 2024-01-2467.47 KBASCIA letter PBAC Asthma Mepolizumab 2024-01-2469.70 KBASCIA letter PBAC Avacopan 2024-01-2463.78 KBASCIA letter PBAC Neocate Syneo 2024-01-24115.84 KBASCIA letter PBAC SLE Anifrolumab 2024-01-2463.50 KB
2024